From the American Cancer Society, ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. A woman's risk of getting ovarian cancer during her lifetime is about 1 in 75. Her lifetime chance of dying from ovarian cancer is about 1 in 100. Host Dr. Renee Allen is joined by Dr. Evelyn Reynolds to discuss critical updates in ovarian cancer, specifically dispelling the myth about ovarian cancer being a "silent killer." Dr. Reynolds an Associate Professor and Division Director of Gynecologic Oncology at the Morehouse School of Medicine. She is board-certified in General Obstetrics and Gynecology and also Gynecologic Oncology.
From Silent Killer to Treatable Disease: Improved Detection Methods for Ovarian Cancer

Transcript
From Silent Killer to Treatable Disease: Improved Detection Methods for Ovarian Cancer
closeReady to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
From the American Cancer Society, ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. A woman's risk of getting ovarian cancer during her lifetime is about 1 in 75. Her lifetime chance of dying from ovarian cancer is about 1 in 100. Host Dr. Renee Allen is joined by Dr. Evelyn Reynolds to discuss critical updates in ovarian cancer, specifically dispelling the myth about ovarian cancer being a "silent killer." Dr. Reynolds an Associate Professor and Division Director of Gynecologic Oncology at the Morehouse School of Medicine. She is board-certified in General Obstetrics and Gynecology and also Gynecologic Oncology.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Updates From the 7th World Symposium Task Force
Integrating Guideline Directed Medical Therapy for Patients with CKD and T2D
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
AHA 2024 and Acoramidis: Impact on the Future of ATTR-CM Patient Care
Respiratory Dysfunction in Neuromuscular Disorders: Evaluating Symptoms
Vorasidenib and mIDH Gliomas: Reviewing the Efficacy Data
Diagnosing and Treating Benign Prostatic Hyperplasia and Overactive Bladder
Bladders, Breakthroughs, and Bold New Therapies: Key Updates at AUA 2025
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?